Nuzenio

Lung Cancer Trial

Lung Cancer Trial news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 13 latest news signals 13 publisher sources 100/100 entity strength

Latest news

What Does Merck (MRK) Lose From Ending Its Late Stage Lung Cancer Trial? - simplywall.stsimplywall.st · Sun, 09 Aug 2026 11:37:53 GMT SKYSCRAPER-03 Trial: Critical Setback for TIGIT Consolidation in Stage III NSCLC - OncodailyOncodaily · Sat, 08 Aug 2026 11:36:12 GMT bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung - BioSpaceBioSpace · Fri, 07 Aug 2026 15:13:11 GMT SystImmune doses first patient in Phase III trial for ES-SCLC - Clinical Trials ArenaClinical Trials Arena · Thu, 06 Aug 2026 10:25:17 GMT Withdrawal Planned for Second-Line Lurbinectedin in SCLC Indication - CancerNetworkCancerNetwork · Wed, 05 Aug 2026 14:09:23 GMT SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - PR NewswirePR Newswire · Wed, 05 Aug 2026 12:00:00 GMT Merck advances sac-TMT into first-line lung cancer redesign after endometrial Phase III win - AllSciAllSci · Wed, 05 Aug 2026 09:44:57 GMT Amplia Therapeutics partners with Lilly on lung cancer combination trial - Yahoo Finance AustraliaYahoo Finance Australia · Tue, 04 Aug 2026 03:06:00 GMT

Timeline

Sun, 09 Aug 2026 11:37:53 GMTWhat Does Merck (MRK) Lose From Ending Its Late Stage Lung Cancer Trial? - simplywall.st

Sat, 08 Aug 2026 11:36:12 GMTSKYSCRAPER-03 Trial: Critical Setback for TIGIT Consolidation in Stage III NSCLC - Oncodaily

Fri, 07 Aug 2026 15:13:11 GMTbioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung - BioSpace

Thu, 06 Aug 2026 10:25:17 GMTSystImmune doses first patient in Phase III trial for ES-SCLC - Clinical Trials Arena

Wed, 05 Aug 2026 14:09:23 GMTWithdrawal Planned for Second-Line Lurbinectedin in SCLC Indication - CancerNetwork

Wed, 05 Aug 2026 12:00:00 GMTSystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - PR Newswire

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Trial4 live mentions Phase III4 live mentions Yahoo Finance Australia3 live mentions SMH3 live mentions Oncology News Central3 live mentions What Does Merck2 live mentions MRK2 live mentions Lose From Ending2 live mentions Its Late Stage2 live mentions Critical Setback2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Lung Cancer Trial.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

13 distinct publisher/source names are currently connected to this entity page.